Literature DB >> 1457409

Expression of platelet-derived endothelial cell growth factor in Escherichia coli and confirmation of its thymidine phosphorylase activity.

A Moghaddam1, R Bicknell.   

Abstract

Platelet-derived endothelial cell growth factor (PD-ECGF) has been expressed in Escherichia coli as a fusion protein with glutathione S-transferase (GST). The fusion protein was purified by one-step affinity chromatography on glutathione-agarose beads, and recombinant PD-ECGF was proteolytically cleaved with thrombin from its GST leader peptide to yield pure protein. Recombinant PD-ECGF stimulated [3H]methylthymidine uptake by endothelial cells in vitro; however, we were unable to detect stimulation of cell proliferation under a wide variety of conditions. We confirm that in accord with the recent report that PD-ECGF and human thymidine phosphorylase are products of the same gene [Furukawa, T., Yoshimura, A., Sumizawa, T., Haraguchi, M., & Akiyama, S. I. (1992) Nature 356, 668] recombinant PD-ECGF has thymidine phosphorylase activity comparable to that of E. coli thymidine phosphorylase. Further, E. coli thymidine phosphorylase was able to mimic the activity of recombinant PD-ECGF in the [3H]methylthymidine uptake assay, and it appears that recombinant PD-ECGF's effect on the uptake of thymidine by endothelial cells may be due to modulation of cellular thymidine pools. The mechanism by which PD-ECGF stimulates angiogenesis remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1457409     DOI: 10.1021/bi00163a024

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  42 in total

1.  Anti-(herpes simplex virus) activity of 4'-thio-2'-deoxyuridines: a biochemical investigation for viral and cellular target enzymes.

Authors:  A Verri; F Focher; R J Duncombe; I Basnak; R T Walker; P L Coe; E de Clercq; G Andrei; R Snoeck; J Balzarini; S Spadari
Journal:  Biochem J       Date:  2000-10-15       Impact factor: 3.857

2.  Structural basis for non-competitive product inhibition in human thymidine phosphorylase: implications for drug design.

Authors:  Kamel El Omari; Annelies Bronckaers; Sandra Liekens; Maria-Jésus Pérez-Pérez; Jan Balzarini; David K Stammers
Journal:  Biochem J       Date:  2006-10-15       Impact factor: 3.857

Review 3.  Thymidine Phosphorylase in Cancer; Enemy or Friend?

Authors:  Yasir Y Elamin; Shereen Rafee; Nemer Osman; Kenneth J O Byrne; Kathy Gately
Journal:  Cancer Microenviron       Date:  2015-08-23

4.  Effects of platelet-derived endothelial cell growth factor/thymidine phosphorylase, substrate, and products in a three-dimensional model of angiogenesis.

Authors:  D P Stevenson; S R Milligan; W P Collins
Journal:  Am J Pathol       Date:  1998-06       Impact factor: 4.307

5.  Molecular cloning, characterization, and expression in Escherichia coli of iron superoxide dismutase cDNA from Leishmania donovani chagasi.

Authors:  S O Ismail; Y A Skeiky; A Bhatia; L A Omara-Opyene; L Gedamu
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

6.  Angiogenesis and lymphangiogenesis of gastric cancer.

Authors:  Yasuhiko Kitadai
Journal:  J Oncol       Date:  2010-03-29       Impact factor: 4.375

7.  Cancer-stromal cell interaction and tumor angiogenesis in gastric cancer.

Authors:  Yasuhiko Kitadai
Journal:  Cancer Microenviron       Date:  2009-12-18

Review 8.  Breast cancer angiogenesis--new approaches to therapy via antiangiogenesis, hypoxic activated drugs, and vascular targeting.

Authors:  A L Harris; H Zhang; A Moghaddam; S Fox; P Scott; A Pattison; K Gatter; I Stratford; R Bicknell
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

Review 9.  Human microvessel endothelial cells: isolation, culture and characterization.

Authors:  P W Hewett; J C Murray
Journal:  In Vitro Cell Dev Biol Anim       Date:  1993-11       Impact factor: 2.416

10.  High expression of thymidine phosphorylase in basal-like breast cancers: Stromal expression in EGFR- and/or CK5/6-positive breast cancers.

Authors:  Shinobu Umemura; Masatoshi Shirane; Susumu Takekoshi; Yutaka Tokuda; Kazushige Mori; Robert Y Osamura
Journal:  Oncol Lett       Date:  2010-03-01       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.